355 filings
Page 4 of 18
CORRESP
ATXI
Avenue Therapeutics Inc
23 Jun 23
Correspondence with SEC
12:00am
UPLOAD
ATXI
Avenue Therapeutics Inc
22 Jun 23
Letter from SEC
12:00am
S-3
ATXI
Avenue Therapeutics Inc
Shelf registration
16 Jun 23
4:31pm
8-K
ATXI
Avenue Therapeutics Inc
22 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:07pm
10-Q
2023 Q1
ATXI
Avenue Therapeutics Inc
Quarterly report
12 May 23
4:15pm
8-K
ATXI
Avenue Therapeutics Inc
12 May 23
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
8:35am
424B3
ATXI
Avenue Therapeutics Inc
4 May 23
Prospectus supplement
4:30pm
EFFECT
ATXI
Avenue Therapeutics Inc
4 May 23
Notice of effectiveness
12:15am
CORRESP
ATXI
Avenue Therapeutics Inc
1 May 23
Correspondence with SEC
12:00am
DEFA14A
ATXI
Avenue Therapeutics Inc
28 Apr 23
Additional proxy soliciting materials
4:15pm
DEF 14A
ATXI
Avenue Therapeutics Inc
Definitive proxy
28 Apr 23
4:06pm
8-K
ATXI
Avenue Therapeutics Inc
17 Apr 23
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol
4:06pm
UPLOAD
ATXI
Avenue Therapeutics Inc
17 Apr 23
Letter from SEC
12:00am
S-1
ATXI
Avenue Therapeutics Inc
IPO registration
10 Apr 23
7:54pm
4
ATXI
Avenue Therapeutics Inc
4 Apr 23
Change in insider ownership
4:08pm
10-K
2022 FY
ATXI
Avenue Therapeutics Inc
Annual report
31 Mar 23
4:18pm
8-K
ATXI
Avenue Therapeutics Inc
30 Mar 23
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights
4:07pm
8-K
ATXI
Avenue Therapeutics Inc
8 Mar 23
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates
4:10pm
8-K
ATXI
Avenue Therapeutics Inc
2 Mar 23
Entry into a Material Definitive Agreement
8:05am
SC 13G/A
CVI Investments, Inc.
14 Feb 23
AVENUE THERAPEUTICS / CVI Investments ownership change
11:22am